NASDAQ:BIOC - Biocept Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.98 +0.03 (+3.16 %) (As of 04/24/2019 04:00 PM ET)Previous Close$0.95Today's Range$0.85 - $0.9852-Week Range$0.66 - $12.15Volume1.66 million shsAverage Volume2.79 million shsMarket Capitalization$18.49 millionP/E RatioN/ADividend YieldN/ABeta2.93 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms. It offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, melanoma, pancreatic biliary cancer, and ovarian cancer. The company sells its cancer diagnostic assays directly to oncologists and other physicians at private and group practices, hospitals, and cancer centers in the United States, as well as markets its clinical trial and research services to pharmaceutical and biopharmaceutical companies, and clinical research organizations. Biocept, Inc. was founded in 1997 and is headquartered in San Diego, California. Receive BIOC News and Ratings via Email Sign-up to receive the latest news and ratings for BIOC and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Medical laboratories Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BIOC Previous Symbol CUSIPN/A CIK1044378 Webwww.biocept.com Phone858-320-8200Debt Debt-to-Equity Ratio0.32 Current Ratio1.30 Quick Ratio1.18Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$3.25 million Price / Sales5.69 Cash FlowN/A Price / Cash FlowN/A Book Value$0.66 per share Price / Book1.48Profitability EPS (Most Recent Fiscal Year)($9.01) Net Income$-24,570,000.00 Net Margins-755.80% Return on Equity-427.45% Return on Assets-212.14%Miscellaneous Employees95 Outstanding Shares18,867,000Market Cap$18.49 million Next Earnings Date5/21/2019 (Estimated) OptionableOptionable Biocept (NASDAQ:BIOC) Frequently Asked Questions What is Biocept's stock symbol? Biocept trades on the NASDAQ under the ticker symbol "BIOC." How were Biocept's earnings last quarter? Biocept Inc (NASDAQ:BIOC) issued its quarterly earnings results on Thursday, March, 28th. The medical research company reported ($1.43) earnings per share for the quarter, beating the Zacks' consensus estimate of ($1.50) by $0.07. The medical research company earned $0.86 million during the quarter, compared to the consensus estimate of $0.95 million. Biocept had a negative net margin of 755.80% and a negative return on equity of 427.45%. View Biocept's Earnings History. When is Biocept's next earnings date? Biocept is scheduled to release their next quarterly earnings announcement on Tuesday, May 21st 2019. View Earnings Estimates for Biocept. What is the consensus analysts' recommendation for Biocept? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biocept in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Biocept. What are Wall Street analysts saying about Biocept stock? Here are some recent quotes from research analysts about Biocept stock: 1. Maxim Group analysts commented, "We are initiating coverage of Buy rating and $3 price target. Biocept’s Target Selector is a liquid biopsy platform which, in addition to providing actionable data based on circulating tumor DNA (ctDNA) analysis, incorporates circulating tumor cell (CTC) analysis which differentiates the company in an increasingly ‘crowded’ liquid biopsy space." (3/26/2019) 2. According to Zacks Investment Research, "Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians. The company offers OncoCEE-BR (TM) test for breast cancer. Biocept, Inc. is headquartered in San Diego, California. " (2/13/2019) Has Biocept been receiving favorable news coverage? Media headlines about BIOC stock have been trending positive recently, InfoTrie reports. The research group scores the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Biocept earned a news sentiment score of 2.5 on InfoTrie's scale. They also assigned news coverage about the medical research company a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. Are investors shorting Biocept? Biocept saw a increase in short interest during the month of March. As of March 15th, there was short interest totalling 863,632 shares, an increase of 71.2% from the February 28th total of 504,596 shares. Based on an average trading volume of 2,868,031 shares, the short-interest ratio is presently 0.3 days. Approximately 7.5% of the shares of the stock are short sold. View Biocept's Current Options Chain. Who are some of Biocept's key competitors? Some companies that are related to Biocept include CBA Florida (CBAI), First Choice Healthcare Solutions (FCHS), Cancer Genetics (CGIX), OpGen (OPGN), Aeon Global Health (AGHC), Avant Diagnostics (AVDX) and Foundation Medicine (FMI). What other stocks do shareholders of Biocept own? Based on aggregate information from My MarketBeat watchlists, some companies that other Biocept investors own include Walmart (WMT), Synergy Pharmaceuticals (SGYP), Kadmon (KDMN), SCYNEXIS (SCYX), AVEO Pharmaceuticals (AVEO), Exelixis (EXEL), IntelliPharmaCeutics Intl (IPCI), Cytori Therapeutics (CYTX), TrovaGene (TROV) and Nymox Pharmaceutical (NYMX). Who are Biocept's key executives? Biocept's management team includes the folowing people: Mr. Michael W. Nall, CEO, Pres & Director (Age 56)Mr. Timothy C. Kennedy, CFO, Sr. VP of Operations & Corp. Sec. (Age 61)Dr. Lyle J. Arnold, Sr. VP of R&D, Chief Scientific Officer and Member of Scientific Advisory Board (Age 72)Dr. Soon Kap Hahn Ph.D., FounderMr. Pavel Tsinberg, Director of Technology Devel. How do I buy shares of Biocept? Shares of BIOC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Biocept's stock price today? One share of BIOC stock can currently be purchased for approximately $0.98. How big of a company is Biocept? Biocept has a market capitalization of $18.49 million and generates $3.25 million in revenue each year. The medical research company earns $-24,570,000.00 in net income (profit) each year or ($9.01) on an earnings per share basis. Biocept employs 95 workers across the globe. What is Biocept's official website? The official website for Biocept is http://www.biocept.com. How can I contact Biocept? Biocept's mailing address is 5810 Nancy Ridge Drive, San Diego CA, 92121. The medical research company can be reached via phone at 858-320-8200 or via email at [email protected] MarketBeat Community Rating for Biocept (NASDAQ BIOC)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 232 (Vote Outperform)Underperform Votes: 264 (Vote Underperform)Total Votes: 496MarketBeat's community ratings are surveys of what our community members think about Biocept and other stocks. Vote "Outperform" if you believe BIOC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIOC will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 4/24/2019 by MarketBeat.com StaffFeatured Article: What is a Call Option?